FTDR vs REGN · P/E 18, rev $1.84B vs P/E 14, rev $14.34B
Frontdoor Inc (FTDR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Frontdoor Inc (FTDR) is a personal services company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported FTDR revenue for 2024-12-31 was $1.84B. Net income was $235.0M. Revenue was up 3.5% from 2023-12-31 to 2024-12-31. FTDR currently screens at market cap $4.47B and trailing P/E 18.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
FTDR currently screens at market cap $4.47B and trailing P/E 18.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the FTDR and REGN stock pages for the full models.
Not investment advice.